Market Newsdesk

November 24, 2020 9:02 pm

BeyondSpring to Present at Two Upcoming Scientific Conferences in December

B
eyondSpring
to present
at
the
62nd American Society of Hematology (ASH) Annual Meeting
and
at the
2020
San Antonio Breast Cancer Symposium

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a poster presentation about the PROTECTIVE-2 Trial (ClinicalTrials.gov ID: NCT03294577) at the 62nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8, 2020. The Company will also present three posters about the PROTECTIVE-1 Trial and PROTECTIVE-2 Trial at the San Antonio Breast Cancer Symposium (SABCS) being held virtually December 8-11, 2020.

Details for the ASH Poster Presentation

Title:		Protective-2 (BPI-2358-106): A Confirmatory Trial to Demonstrate Superiority of the Plinabulin+Pegfilgrastim (Plin/Peg) Combination Versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia (CIN) in Breast Cancer (BC) Patients (pts)
Abstract:		817
Session:		201. Granulocytes, Monocytes, and Macrophages: Poster I Hematology Disease Topics & Pathways: Therapies, Combinations, Clinically relevant
Date/Time:		Saturday, December 5, 2020 from 7:00 a.m.-3:30 p.m. PST
Presenter:		Douglas W. Blayney, M.D. (Stanford University)

Details for the SABCS
Poster
Presentation
s

Title:		Plinabulin and Pegfilgrastim (Plin+Peg) versus Peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain
Publication #:		PS11-15
Date/Time:		starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand)
Presenter:		Douglas W. Blayney, M.D. (Stanford University)

———–

Title:		Protective-2 (bpi-2358-106): a confirmatory trial to demonstrate superiority of the plinabulin+pegfilgrastim (plin/peg) combination versus standard of care pegfilgrastim for the prevention of chemotherapy-induced neutropenia (cin) in breast cancer (bc) patients (pts)
Publication #:		OT-06-02
Date/Time:		starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand)
Presenter:		Douglas W. Blayney, M.D. (Stanford University)

———–

Title:		Differential efficacy of Pegfilgrastim (Peg) in patients (pts) with breast cancer (BC) versus other cancer types for the prevention of Docetaxel (Doc) chemotherapy-induced neutropenia (CIN)
Publication #:		PS13-34
Date/Time:		starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand)
Presenter:		Douglas W. Blayney, M.D. (Stanford University)

———–

Title:		Superior Protection Against Profound Neutropenia with the Plinabulin/Pegfilgrastim (Plin/Peg) Combination versus Pegfilgrastim (Peg) Monotherapy In Breast Cancer (BC) Patients Receiving TAC Chemotherapy: Final Results from Protective-2 (BPI-2358-106)
Date/Time:		starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand)
Presenter:		Douglas W. Blayney, M.D. (Stanford University)

About
BeyondSpring

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Investor Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
[email protected]

Media Contact:

Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
[email protected]

November 24, 2020 8:54 pm

ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Credit Acceptance Corporation Investors of Important December 1 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – CACC

PR Newswire

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Credit Acceptance Corporation (NASDAQ: CACC) between November 1, 2019 and August 28, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Credit Acceptance investors under the federal securities laws.

To join the Credit Acceptance class action, go to http://www.rosenlegal.com/cases-register-1851.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was topping off the pools of loans that they packaged and securitized with higher-risk loans; (2) Credit Acceptance was making high-interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (3) the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (4) Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (5) as a result, the Company was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (6) as a result of the foregoing, Defendant’s positive statements about the Company’s business, operations, and adherence to appropriate laws and regulations were materially misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1851.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-trusted-investor-counsel-reminds-credit-acceptance-corporation-investors-of-important-december-1-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–cacc-301180255.html

SOURCE Rosen Law Firm, P.A.

November 24, 2020 8:50 pm

ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA

PR Newswire

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.

On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma’s “unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon.” Sonoma continued that the financial statements for this time period “contained material errors” and that “the Company will need to restate them.”

On this news, Sonoma’s share price fell $1.10 per share, or more than 14%, over the next few trading days to close at $6.63 per share on November 20, 2020.

Rosen Law Firm is preparing a securities lawsuit on behalf of Sonoma shareholders. If you purchased securities of Sonoma please visit the firm’s website at http://www.rosenlegal.com/cases-register-1992.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-leading-law-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc–snoa-301180207.html

SOURCE Rosen Law Firm, P.A.

November 24, 2020 8:48 pm

ROSEN, A TOP RANKED LAW FIRM, Files First Securities Class Action Lawsuit Against JOYY Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – YY

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of JOYY Inc. (NASDAQ: YY), between April 28, 2016 and November 18, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for JOYY investors under the federal securities laws.

To join the JOYY class action, go to http://www.rosenlegal.com/cases-register-1988.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) the majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company’s acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1988.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

——————————-

Contact Information:
      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40^th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

November 24, 2020 8:40 pm

CORRECTION – Avricore Health Closes $626,000 First Tranche of Financing

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) — In a release issued under the same headline on Friday, November 13, by Avricore Health Inc. (TSXV: AVCR), the units issued figure was meant to be 6,260,000, not 6,360,000. The corrected release follows:

A
VRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces it has closed the first tranche of its non-brokered private placement for gross proceeds of $626,000. The Company will issue 6,260,000 units at $0.10 per unit and will pay finders fees totaling $22,500 and issue 225,000 finders warrants. Insiders participated in the aggregate amount of $55,000 for 550,000 units. Placement proceeds will be used for general working capital purposes.

“Despite a very challenging year, our company continues to march down the field in a positive way and we are really pleased to not only be able to raise capital, but also raise it at a premium,” said Avricore Health CEO, Hector Bremner. “While the decision horizon for some investors is further out than this first group, we are confident in the enthusiasm and momentum we have to close out the balance.”

Each Unit consists of one common share and one transferrable share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional common share for a period of 12 months from the closing date of the offering at a price of $0.15 per common share provided that if the closing price of the common shares of the Company on any stock exchange or quotation system on which the common shares are then listed or quoted is equal to or greater than $0.20 for a period of fifteen (15) consecutive trading days, the Company will have the right to accelerate the expiry of the warrants to a date that is not less than ten (10) business days from the date notice is given. The Company may pay finders fees of up to 5% cash and 5% finders warrants on a portion of the placement.

Closing of the Private Placement is subject to final acceptance by the TSX Venture Exchange. All securities issued in connection with the Private Placement will be subject to a four-month hold period from the closing date under applicable Canadian securities laws.

The Private Placement securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act”), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

Contact:

Hector Bremner, CEO 604-773-8943
[email protected]
www.avricorehealth.com

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company’s goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

November 24, 2020 8:33 pm

ROSEN, A LEADING LAW FIRM, Reminds First American Financial Corp. Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – FAF

ROSEN, A LEADING LAW FIRM, Reminds First American Financial Corp. Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – FAF

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of First American Financial Corp. (NYSE: FAF) between February 17, 2017 and October 22, 2020, inclusive (the “Class Period”), of the important December 24, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for First American investors under the federal securities laws.

To join the First American class action, go to http://www.rosenlegal.com/cases-register-1662.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) First American failed to implement basic security standards to protect its customers’ sensitive personal information and data; (2) First American faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1662.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124006064/en/

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40^th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo

November 24, 2020 8:27 pm

VitalHub Reports an Increase in Revenue of 33% and an Increase of Annual Contract Value of 143% over the prior year.

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management’s Discussion and Analysis report for the three and nine months ended September 30, 2020 and 2019 with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedar.com.

When asked to comment on the quarter Dan Matlow said:

“I am encouraged that our focus on responsible growth both organically and by M&A is showing positive results. Given the timing of our recent acquisitions, Q3 only saw a modest contribution to recognized revenue from our recent Intouch with Health and Transforming Systems Ltd. acquisitions. Notwithstanding this, both acquisitions have made significant impacts in terms of new, large-scale recurring licensing transactions which will positively impact future periods. We grew our annualized contract value (“ACV”) by 81% compared to the prior quarter, which was achieved through organic growth of $543,258 or 7.25%, in addition to the lift attributable to the acquisitions of $5,525,327 or 73.8%. We are pleased to see this same pattern of organic growth continuing into Q4 as well.”

COMPANY HIGHLIGHTS

Revenue for the three months ended September 30, 2020 was $3,192,166 as compared to $2,395,662 for the three months ended September 30, 2019, an increase of $796,504 or 33.2%. Revenue for the nine months ended September 30, 2020 was $8,711,060 as compared to $7,667,264 for the nine months ended September 30, 2019, an increase of $1,043,796 or 13.6%.

The Company defines Annualized Contract Value (“ACV”) of recurring revenue as the contracted annual renewable software license fees and maintenance services. For the quarter ACV grew organically by $543,258 or 7.25% and by $5,525,327 or 73.8% from acquisitions as compared to the prior quarter ended June 30, 2020 of $7,491,841. The ACV of recurring revenue at September 30, 2020 was $13,560,696 as compared to $5,579,377 at September 30, 2019, an increase of 143%. ACV is a non-IFRS measure.

Net loss for the three months ended September 30, 2020 was $1,065,505 as compared to a loss of $475,295 for the three months ended September 30, 2019, an increase of $590,210. Net loss for the nine months ended September 30, 2020 was $1,450,504 as compared to $625,774 for the nine months ended September 30, 2019, an increase of $824,730. The majority of the loss was due to business acquisition, restructuring and integration costs of $820,237 for the quarter and $1,075,803 for the nine months ended September 30, 2020.

EBITDA (defined as earnings before interest, taxation, depreciation and amortization) for the three months ended September 30, 2020 was ($419,362) as compared to $445,290 for the three months ended September 30, 2019, a decrease of $864,852. EBITDA for the nine months ended September 30, 2020 was $273,840 as compared to $1,349,939 for the nine months ended September 30, 2019. The majority of the decrease in EBITDA was due to business acquisition, restructuring and integration costs of $820,237 for the quarter and $1,075,803 for the nine months ended September 30, 2020. EBITDA is a non-IFRS measure.

Adjusted EBITDA (defined as earnings before interest, taxation, depreciation, amortization, share based compensation, business acquisition, restructuring and integration costs and other
one time
costs) for the three months ended September 30, 2020 was $502,595 as compared to $523,669 for the three months ended September 30, 2019, a decrease of $21,074. Adjusted EBITDA for the nine months ended September 30, 2020 was $1,539,136 as compared to $1,573,116 for the nine months ended September 30, 2019. Adjusted EBITDA is a non-IFRS measure.

Adjusted EBITDA as a percentage of revenue for the three months ended September 30, 2020 was 16% as compared to 22% for the three months ended September 30, 2019. Adjusted EBITDA as a percentage of revenue for the nine months ended September 30, 2020 was 18% as compared to 23% for the nine months ended September 30, 2019. Due to the relatively high amortization of intangibles from acquisitions and periodic restructuring and integration costs from acquisitions management believes that Adjusted EBITDA as a percentage of revenue is an important key performance indicator to measure. Adjusted EBITDA as a percentage of revenue is a non-IFRS measure.

During the quarter, the Company completed two acquisitions, marking a total of eight acquisitions to date. Intouch with Health Ltd. (“Intouch”), and Transforming Systems Ltd. (“Transform”), were acquired with the purchase of all the issued and outstanding shares. Intouch had total revenue (unaudited) of GBP 3,141,975 of which GBP 1,329,198 were recurring for the 12-month period ending July 31, 2020. Transform had total revenue (unaudited) of GBP 2,218,192, of which GBP 1,880,962 were recurring for the 12-month period ending July 31, 2020.

On Sept 15, 2020, the Company closed a non-brokered private placement of 1,000,000 common shares at a price per share of $2.20 for total gross proceeds of $2,200,000. Use of proceeds from the Offering will be for future acquisition purposes, and to advance the Company’s M&A strategy.

Subsequent to the quarter, the Company closed a bought deal offering with gross proceeds of approximately $
16,996,248
. A total of 5,860,775 common shares of the Company were sold at a price of $2.90 per common share.

ABOUT VITALHUB:

Software for Health and Human Services providers designed to simplify the user experience & optimize outcomes.

VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”.

CAUTIONARY STATEMENT:

This press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT INFORMATION

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
[email protected]

November 24, 2020 8:26 pm

Continental Resources Announces Early Results And Upsizing Of Cash Tender Offers

PR Newswire

OKLAHOMA CITY, Nov. 24, 2020 /PRNewswire/ — Continental Resources, Inc. (NYSE: CLR) (“Continental” or the “Company”) announced today the results to date of Continental’s previously announced cash tender offers (the “Tender Offers”) to purchase up to $1.0 billion aggregate principal amount (the “Aggregate Maximum Tender Amount”) of its outstanding 5.0% senior notes due 2022 (the “2022 Notes”) and 4.5% senior notes due 2023 (the “2023 Notes” and collectively, the “Notes”), subject to a limit of $200 million aggregate principal amount of 2023 Notes that may be purchased in the Tender Offers (the “2023 Series Cap”).

Logo – https://mma.prnewswire.com/media/95419/continental_resources_logo.jpg

The Company has amended the Aggregate Maximum Tender Amount to increase the aggregate principal amount of Notes subject to the Tender Offers from $1.0 billion to approximately $1.27 billion, as well as to increase the 2023 Series Cap to $800 million. All other terms of the Tender Offers remain unchanged. Based on information provided by D.F. King and Co., the tender agent for the Tender Offers, approximately $1.47 billion aggregate principal amount of Notes were validly tendered (and not validly withdrawn) at or prior to 5:00 p.m., New York City time, on November 24, 2020 (the “Early Tender Date”). The following table sets forth the approximate aggregate principal amounts of each series of Notes that were validly tendered (and not validly withdrawn) as of the Early Tender Date and the principal amounts that, subject to satisfaction of the conditions to the Tender Offers described below, are expected to be accepted for purchase pursuant to the Tender Offers:


Title of Notes	CUSIP Numbers / ISIN	Acceptance Priority Level	Principal Amount Outstanding Prior to the Tender Offers(1)	Total Consideration (2)(3)	Principal Amount of Notes Tendered	Principal Amount of Notes Expected to Be Accepted for Purchase	Proration Factor(4)
5.0% Senior Notes due 2022	212015AH4; 212015AG6; U21180AA9	1	$ 1,100,000,000	$ 1,002.50	$ 469,218,000	$ 469,218,000	100.0%
4.5% Senior Notes due 2023	212015AL5	2	$ 1,449,625,000	$ 1,030.00	$ 1,001,075,000	$ 800,000,000	79.9%

_________________________
(1)	As of the date of the Offer to Purchase (as defined below).
(2)	Holders will also receive accrued and unpaid interest from the applicable last interest payment with respect to the Notes accepted for purchase to, but not including, the Early Settlement Date (as defined below).
(3)	Includes the Early Tender Premium (as defined below).
(4)	The final proration factor has been rounded to the nearest tenth of a percentage point for presentation purposes.

Subject to satisfaction of the conditions to the Tender Offers set forth in the Offer to Purchase dated November 10, 2020 (the “Offer to Purchase”), the Company expects to accept and pay for Notes tendered prior to the Early Tender Date, subject to the proration described herein, on or about November 25, 2020 (the “Early Settlement Date”). Holders of Notes that have been accepted for purchase in connection with the Early Tender Date will receive the applicable Total Consideration set forth in the table above, which includes an early tender premium of $30.00 per $1,000 principal amount of the Notes accepted for purchase (the “Early Tender Premium”). The deadline for holders to validly withdraw tenders of Notes has passed. Accordingly, tendered Notes may no longer be withdrawn or revoked, except in certain limited circumstances where additional withdrawal or revocation rights are required by law.

Because the Aggregate Maximum Tender Amount of Notes were tendered and not withdrawn prior to the Early Tender Date, the Company does not expect to accept for purchase any tenders of Notes after the Early Tender Date.

The Tender Offers are subject to the satisfaction of the conditions described in the Offer to Purchase. Such conditions may be waived by the Company in its sole discretion, subject to applicable law. Any waiver of a condition by the Company will not constitute a waiver of any other condition.

The dealer manager for the Tender Offers is BofA Securities. Any questions regarding the terms of the Tender Offers should be directed to the Dealer Manager, BofA Securities at (980) 386-6026 (all call) or [email protected]. The information agent and tender agent is D.F. King & Co., Inc. Any questions regarding procedures for tendering Notes or requests for copies of the Offer to Purchase or other documents relating to the Tender Offers should be directed to the information agent for the Tender Offers, D.F. King & Co., Inc., at (877) 732-3619 (toll-free), (212) 269-5550 (all others) or [email protected], or by visiting www.dfking.com/clr.

This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The offer is being made solely pursuant to the terms and conditions set forth in the Offer to Purchase. The Company’s obligation to accept for purchase and to pay for the Notes validly tendered in any Tender Offer is subject to and conditioned on the satisfaction or waiver of the conditions described in the Offer to Purchase, including the completion of the Company’s separately announced offering of 5.75% Senior Notes due 2031 (the “Debt Financing”). Nothing contained herein shall constitute an offer of the securities that are the subject of the Debt Financing.

About Continental Resources

Continental Resources (NYSE: CLR) is a top 10 independent oil producer in the U.S. and a leader in America’s energy renaissance. Based in Oklahoma City, Continental is the largest leaseholder and the largest producer in the nation’s premier oil field, the Bakken play of North Dakota and Montana. The Company also has significant positions in Oklahoma, including its SCOOP Woodford and SCOOP Springer discoveries and the STACK plays. With a focus on the exploration and production of oil, Continental has unlocked the technology and resources vital to American energy independence and our nation’s leadership in the new world oil market. In 2020, the Company will celebrate 53 years of operations. For more information, please visit www.CLR.com.

Cautionary Statement for the Purpose of the “Safe Harbor” Provisions of the Private Securities Litigation Reform Act of 1995

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements included in this press release other than statements of historical fact, including, but not limited to, expectations regarding the completion of the Debt Financing and the Tender Offers are forward-looking statements. When used in this press release, the words “could,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “budget,” “target,” “plan,” “continue,” “potential,” “guidance,” “strategy,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.

Forward-looking statements are based on the Company’s current expectations and assumptions about future events and currently available information as to the outcome and timing of future events. Although the Company believes these assumptions and expectations are reasonable, they are inherently subject to numerous business, economic, competitive, regulatory and other risks and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control. No assurance can be given that such expectations will be correct or achieved or that the assumptions are accurate. The risks and uncertainties include, but are not limited to, commodity price volatility; the geographic concentration of our operations; financial market and economic volatility; the effects of any national or international health crisis; the inability to access needed capital; the risks and potential liabilities inherent in crude oil and natural gas drilling and production and the availability of insurance to cover any losses resulting therefrom; difficulties in estimating proved reserves and other reserves-based measures; declines in the values of our crude oil and natural gas properties resulting in impairment charges; our ability to replace proved reserves and sustain production; our ability to pay future dividends or complete share repurchases; the availability or cost of equipment and oilfield services; leasehold terms expiring on undeveloped acreage before production can be established; our ability to project future production, achieve targeted results in drilling and well operations and predict the amount and timing of development expenditures; the availability and cost of transportation, processing and refining facilities; legislative and regulatory changes adversely affecting our industry and our business, including initiatives related to hydraulic fracturing and greenhouse gas emissions; increased market and industry competition, including from alternative fuels and other energy sources; and the other risks described under Part I, Item 1A. Risk Factors and elsewhere in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, our Forms 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, registration statements and other reports filed from time to time with the SEC, and other announcements the Company makes from time to time.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which such statement is made. Should one or more of the risks or uncertainties described in this press release occur, or should underlying assumptions prove incorrect, the Company’s actual results and plans could differ materially from those expressed in any forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Except as otherwise required by applicable law, the Company undertakes no obligation to publicly correct or update any forward-looking statement whether as a result of new information, future events or circumstances after the date of this report, or otherwise.

Investor Contact:		Media Contact:
Rory Sabino		Kristin Thomas
Vice President, Investor Relations		Senior Vice President, Public Relations
405-234-9620		405-234-9480
[email protected]		[email protected]

Lucy Guttenberger
Investor Relations Analyst
405-774-5878
[email protected]

View original content:http://www.prnewswire.com/news-releases/continental-resources-announces-early-results-and-upsizing-of-cash-tender-offers-301180244.html

SOURCE Continental Resources

November 24, 2020 8:04 pm

ROSEN, A TOP RANKED FIRM, Reminds Aurora Cannabis Inc. Investors of Important December 1 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ACB

PR Newswire

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) Aurora’s purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that Aurora would record significant goodwill and asset impairment charges; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1965.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-top-ranked-firm-reminds-aurora-cannabis-inc-investors-of-important-december-1-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–acb-301180155.html

SOURCE Rosen Law Firm, P.A.

November 24, 2020 8:03 pm

InMed Announces Election of Directors

PR Newswire

VANCOUVER, BC, Nov. 24, 2020 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today confirmed that, at its annual general and special meeting of shareholders held on November 20, 2020 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 7, 2020, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

Director	Votes For		Withheld Votes
Director	Number	Percentage	Number	Percentage
Eric A. Adams	639,176	90.84%	64,464	9.16%
Adam Cutler	654,431	93.01%	49,209	6.99%
William J. Garner	644,945	91.66%	58,695	8.34%
Andrew Hull	654,149	92.97%	49,491	7.03%
Catherine Sazdanoff	653,532	92.88%	50,108	7.12%

InMed filed a report of voting results on SEDAR at www.sedar.com on November 24, 2020.

About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: leading the way in the clinical development of CBN; developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTOSTOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

View original content:http://www.prnewswire.com/news-releases/inmed-announces-election-of-directors-301180215.html

SOURCE InMed Pharmaceuticals Inc.